Xcout IntelNewAmsterdam Pharma Co N.V. competitors & alternatives
The 12 closest competitors and alternatives to NewAmsterdam Pharma Co N.V. among biotech companies — ranked by similarity to what NewAmsterdam Pharma Co N.V. actually does, not by market-cap band.
Subscribe to see NewAmsterdam Pharma Co N.V.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About NewAmsterdam Pharma Co N.V.
NewAmsterdam Pharma Company N.V. is a biopharmaceutical firm currently in the clinical development phase, committed to enhancing therapeutic options for individuals living with metabolic diseases. The company's primary experimental treatment, obicetrapib, is an innovative, selective agent designed to inhibit Cholesteryl Ester Transfer Protein (CETP). Clinical trials have shown this compound to be effective in both lowering "bad" low-density lipoprotein cholesterol (LDL-C) and significantly elevating "good" high-density lipoprotein cholesterol (HDL-C) simultaneously. Founded in 2019, this Dutch company maintains its headquarters in Naarden.
NewAmsterdam Pharma Co N.V. at a glance
NewAmsterdam Pharma Co N.V. is a biotech company headquartered in Naarden, Netherlands. Xcout tracks 19 named people at NewAmsterdam Pharma Co N.V., including Michael Harvey Davidson FACC Facp. (CEO, President & Executive Director). Xcout recorded 15 job postings from NewAmsterdam Pharma Co N.V. in the last 90 days.
NewAmsterdam Pharma Co N.V. leadership
- Michael Harvey Davidson FACC Facp.CEO, President & Executive Director
- Douglas F. KlingChief Operating Officer
- Mayur Amrat SomaiyaChief Financial Officer
- Louise KooijChief Accounting Officer
- Juliette AudetChief Strategy & Business Officer
- Marc DitmarschChief Development Officer
13 more named people on record for NewAmsterdam Pharma Co N.V., with roles, board committees and tenure — see the full roster →
Hiring at NewAmsterdam Pharma Co N.V.
Xcout recorded 15 job postings from NewAmsterdam Pharma Co N.V. in the last 90 days, from a hiring record Xcout has kept since June 2026.
The weekly hiring trend, the roles and locations behind it — see NewAmsterdam Pharma Co N.V.'s hiring signals →
Top 12 NewAmsterdam Pharma Co N.V. competitors
Ranked by semantic similarity — how close each company is to NewAmsterdam Pharma Co N.V. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotech company
Evotec SE operates globally as a dedicated partner, specializing in the discovery and advancement of new pharmaceutical products for the biotechnology and pharmaceutical sectors. Its comprehensive research and development initiatives encompass a broad spectrum of medical areas, such as metabolic disorders (including diabetes and its complications), fibrosis, infectious conditions, central nervous system (CNS) diseases, oncology, pain management, inflammatory ailments, immunological dysfunctions, rare diseases, respiratory conditions, and women's health. The company maintains strategic alliances and collaborations with numerous prominent organizations, including Bayer AG, Lilly, Chinook Therapeutics, Novo Nordisk A/S, Galapagos, Pfizer Inc., CONBA Pharmaceutical Co., Ltd., Bristol Myers Squibb Company, Zhejiang JingXin Pharmaceutical Co., Ltd, Kazia Therapeutics, Apeiron Biologics, and Takeda Pharmaceuticals. Established in 1993, the company was formerly known as Evotec AG, changing its name to Evotec SE in April 2019. Its corporate headquarters are located in Hamburg, Germany.
Biotechnology & CRO
Gubra is a Danish biotech and contract research organization (CRO) specializing in preclinical peptide drug discovery, metabolic research, and advanced imaging services.
Biotechnology
Phlox Therapeutics is a private biotechnology company pioneering RNA-based gene therapies to alleviate and cure severe genetic heart diseases and cardiomyopathies. Headquartered in Naarden, Netherlands, the company focuses on innovative cardiovascular treatments.
Biotechnology
TargED Biopharmaceuticals is a Netherlands-based biotechnology company that develops first-class biological drugs to improve the treatment of thrombosis. The company utilizes small antibodies to deliver enzymes directly to blood clots, aiming to provide targeted thrombolysis for patients suffering from various thrombotic disorders.
Life Science
Gemphire Therapeutics was a U.S. clinical-stage biopharmaceutical company developing gemcabene, an investigational lipid-modulating drug intended to treat dyslipidemia and related cardiovascular and metabolic conditions. It served patients with difficult-to-treat lipid disorders, including severe hypertriglyceridemia and familial hypercholesterolemia.
Similar biotech company
NewcelX Ltd., a biotechnology firm established in 2008 and based in Zurich, Switzerland, is dedicated to advancing groundbreaking therapeutic solutions. The company's focus lies in developing innovative treatments, utilizing both cell-based and small-molecule approaches, to address challenging neurodegenerative and metabolic diseases.
Biotechnology
Cirius Therapeutics, Inc. is a clinical-stage pharmaceutical company headquartered in Grand Rapids, Michigan, focused on developing innovative therapies for metabolic and liver diseases.
Biotechnology
Amplio Pharma is a pharmaceutical company founded in 2020 that develops proprietary drug products to significantly amplify the efficacy of existing pharmaceutical treatments. The company is headquartered in Leiden, Netherlands.
Biotechnology
Mosanna Therapeutics is a biopharmaceutical company with offices in Redwood City, California and Basel, Switzerland. The company focuses on developing novel treatments for metabolic and cardiovascular diseases. It launched with $80 million in funding to advance its clinical pipeline.
Similar biotech company
River BioMedics is a Dutch biotechnology company headquartered in Enschede, Netherlands, founded in 2018. The company focuses on cardiovascular drug discovery by utilizing proprietary 3D human engineered heart tissue models to address unmet medical needs.
Similar biotech company
89bio is a clinical-stage biopharmaceutical company that develops innovative therapies for patients with liver and cardiometabolic diseases. The company utilizes its expertise in FGF21 as a master metabolic regulator to create treatments, such as pegozafermin, for conditions with limited or no approved therapeutic options.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of NewAmsterdam Pharma Co N.V. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for NewAmsterdam Pharma Co N.V.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →